327 related articles for article (PubMed ID: 31404499)
1. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.
Slebos DJ; Shah PL; Herth FJF; Pison C; Schumann C; Hübner RH; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Perez T; Skowasch D; Deslee G; Marceau A; Sciurba FC; Gosens R; Hartman JE; Srikanthan K; Duller M; Valipour A;
Am J Respir Crit Care Med; 2019 Dec; 200(12):1477-1486. PubMed ID: 31404499
[No Abstract] [Full Text] [Related]
2. Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3).
Slebos DJ; Degano B; Valipour A; Shah PL; Deslée G; Sciurba FC;
BMC Pulm Med; 2020 Feb; 20(1):41. PubMed ID: 32054473
[TBL] [Abstract][Full Text] [Related]
3. Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.
Valipour A; Shah PL; Herth FJ; Pison C; Schumann C; Hübner RH; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Perez T; Skowasch D; Deslee G; Marceau A; Sciurba FC; Gosens R; Hartman JE; Conway F; Duller M; Mayse M; Norman HS; Slebos DJ;
Int J Chron Obstruct Pulmon Dis; 2020; 15():2807-2816. PubMed ID: 33177818
[TBL] [Abstract][Full Text] [Related]
4. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes.
Pison C; Shah PL; Slebos DJ; Ninane V; Janssens W; Perez T; Kessler R; Deslee G; Garner JL; Hartman JE; Degano B; Mayr A; Mayse M; Peterson AD; Valipour A
Respir Res; 2021 Feb; 22(1):62. PubMed ID: 33608007
[TBL] [Abstract][Full Text] [Related]
5. Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2.
Conway F; Tonkin J; Valipour A; Pison C; Schumann C; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Skowasch D; Johnson PJ; Slebos DJ; Shah PL;
Respiration; 2022; 101(11):1069-1074. PubMed ID: 36302345
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of bilateral targeted lung denervation in patients with COPD.
Valipour A; Asadi S; Pison C; Jondot M; Kessler R; Benneddif K; Deslee G; Verdier M; Slebos DJ; Mayse M
Int J Chron Obstruct Pulmon Dis; 2018; 13():2163-2172. PubMed ID: 30038492
[TBL] [Abstract][Full Text] [Related]
7. Targeted lung denervation for moderate to severe COPD: a pilot study.
Slebos DJ; Klooster K; Koegelenberg CF; Theron J; Styen D; Valipour A; Mayse M; Bolliger CT
Thorax; 2015 May; 70(5):411-9. PubMed ID: 25739911
[TBL] [Abstract][Full Text] [Related]
8. Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients.
Valipour A; Shah PL; Pison C; Ninane V; Janssens W; Perez T; Kessler R; Deslee G; Garner J; Abele C; Hartman JE; Slebos DJ;
Respiration; 2019; 98(4):329-339. PubMed ID: 31220851
[TBL] [Abstract][Full Text] [Related]
9. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
10. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Anzueto A; Barjaktarevic IZ; Siler TM; Rheault T; Bengtsson T; Rickard K; Sciurba F
Am J Respir Crit Care Med; 2023 Aug; 208(4):406-416. PubMed ID: 37364283
[TBL] [Abstract][Full Text] [Related]
11. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
12. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
[TBL] [Abstract][Full Text] [Related]
13. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
[TBL] [Abstract][Full Text] [Related]
14. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.
Dransfield MT; Kunisaki KM; Strand MJ; Anzueto A; Bhatt SP; Bowler RP; Criner GJ; Curtis JL; Hanania NA; Nath H; Putcha N; Roark SE; Wan ES; Washko GR; Wells JM; Wendt CH; Make BJ;
Am J Respir Crit Care Med; 2017 Feb; 195(3):324-330. PubMed ID: 27556408
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
Zhou Y; Zhong NS; Li X; Chen S; Zheng J; Zhao D; Yao W; Zhi R; Wei L; He B; Zhang X; Yang C; Li Y; Li F; Du J; Gui J; Hu B; Bai C; Huang P; Chen G; Xu Y; Wang C; Liang B; Li Y; Hu G; Tan H; Ye X; Ma X; Chen Y; Hu X; Tian J; Zhu X; Shi Z; Du X; Li M; Liu S; Yu R; Zhao J; Ma Q; Xie C; Li X; Chen T; Lin Y; Zeng L; Ye C; Ye W; Luo X; Zeng L; Yu S; Guan WJ; Ran P
N Engl J Med; 2017 Sep; 377(10):923-935. PubMed ID: 28877027
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
18. Use of CAPTURE to Identify Individuals Who May or May Not Require Treatment for Chronic Obstructive Pulmonary Disease.
Li Y; Wen F; Ma Q; Chen R; Sun Y; Liu T; Gu C; Hu S; Song J; Compton C; Zheng J; Zhong N; Jones P
Am J Respir Crit Care Med; 2023 Aug; 208(4):435-441. PubMed ID: 37315325
[No Abstract] [Full Text] [Related]
19. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
